Opinion/decision on a Paediatric investigation plan (PIP): Leqvio, Inclisiran sodium, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Endocrinology-Gynaecology-Fertility-Metabolism, PIP number: P/0322/20

Submitted by Anonymous (not verified) on 13 September 2024 - 8:51

Opinion/decision on a Paediatric investigation plan (PIP): Leqvio, Inclisiran sodium, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Endocrinology-Gynaecology-Fertility-Metabolism, PIP number: P/0322/2023

Opinion/decision on a Paediatric investigation plan (PIP): Imjudo, Tremelimumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0302/2023

Submitted by Anonymous (not verified) on 13 September 2024 - 8:49

Opinion/decision on a Paediatric investigation plan (PIP): Imjudo, Tremelimumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0302/2023

Opinion/decision on a Paediatric investigation plan (PIP): Imfinzi, durvalumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0301/2023

Submitted by Anonymous (not verified) on 13 September 2024 - 8:46

Opinion/decision on a Paediatric investigation plan (PIP): Imfinzi, durvalumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0301/2023

Opinion/decision on a Paediatric investigation plan (PIP): Namuscla, Mexiletine hydrochloride, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Other, PIP number: P/0300/2023

Submitted by Anonymous (not verified) on 13 September 2024 - 8:24

Opinion/decision on a Paediatric investigation plan (PIP): Namuscla, Mexiletine hydrochloride, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Other, PIP number: P/0300/2023

Opinion/decision on a Paediatric investigation plan (PIP): Aimovig, erenumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neurology, PIP number: P/0299/2023

Submitted by Anonymous (not verified) on 13 September 2024 - 8:18

Opinion/decision on a Paediatric investigation plan (PIP): Aimovig, erenumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neurology, PIP number: P/0299/2023

Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - June 2024, Online, European Medicines Agency, Amsterdam, the Netherlands, from 26 June 2024, 10:00 (CEST) to 26 June 2024, 12:00 (CEST)

Submitted by Anonymous (not verified) on 13 September 2024 - 8:13

Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - June 2024, Online, European Medicines Agency, Amsterdam, the Netherlands, from 26 June 2024, 10:00 (CEST) to 26 June 2024, 12:00 (CEST)

ESIM Winter 2025

Submitted by Aneta on 12 September 2024 - 15:10

Dear EFIM Members,

We are pleased to announce that the Swedish Society of Internal Medicine will be hosting the13th Winter School of the European School of Internal Medicine, in February from 9th– 15th 2025 in Björkliden, Sweden.

It will be the final edition for the Swedish Society hosting the winter School in Björkliden, Sweden, and as every year it will offer very active educational programme, bringing together residents from across Europe to advance knowledge, share best practices, and foster connections.

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More
randomness